|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 USD | 0.00% |
|
-20.00% | -91.90% |
| 04-10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
| 03-15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Sorrento Therapeutics, Inc. announced the appointment of Amar Singh as Executive Vice President and Chief Business Officer. In this role, Mr. Singh will be responsible for overseeing Sorrento's partnering activities. He brings over 25 years of experience in business and commercial development, strategic planning and operations to Sorrento.
Mr. Singh joins Sorrento from Synta Pharmaceuticals, where he was a Senior Vice President and Chief Business Officer.
| 1st Jan change | Capi. | |
|---|---|---|
| -91.90% | 5.44M | |
| +20.17% | 126B | |
| +24.67% | 118B | |
| +25.07% | 27.87B | |
| -17.74% | 20.95B | |
| -15.57% | 16.92B | |
| -15.21% | 16.18B | |
| +11.91% | 14.84B | |
| -47.10% | 14.79B | |
| +54.50% | 14.08B |
SORRENTO THERAPEUTICS, INC. 
